Chimeric Antigen Receptor T-Cell Therapy-Associated Infections in Hematologic Malignancies: A Real-World Pharmacovigilance Analysis [0.03%]
嵌合抗原受体T细胞疗法相关感染的血液系统恶性肿瘤药物警戒分析
Xiangyang Ding,Kexin Ai,Suwan Wu et al.
Xiangyang Ding et al.
Chimeric antigen receptor T-cell therapy-related adverse events have become a focus of clinical attention. However, a comprehensive study of infection-related adverse events remains scarce, especially for high-risk, life-threatening infecti...
Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation [0.03%]
清髓性HLA配型相合异基因造血细胞移植后，环磷酰胺比他克莫司/甲氨蝶呤具有更好的慢性移植物抗宿主病无进展生存优势
Alfonso Molina,Quenton Rashawn Bubb,Hrishikesh K Srinagesh et al.
Alfonso Molina et al.
Introduction: Graft-versus-host disease (GVHD) has been a significant barrier to successful myeloablative (MAC) allogeneic hematopoietic cell transplantation (HCT). Traditional GVHD prophylaxis with calcineurin inhibitor ...
Adverse Social Determinants Independently Predict Outcomes After Allogeneic HSCT [0.03%]
不利的社会决定因素独立预测allo-HSCT后的预后
Maria Huguet,Mireia Morgades,Mercè Riquelme-Olivares et al.
Maria Huguet et al.
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for hematologic diseases but remains associated with substantial morbidity and nonrelapse mortality (NRM). The impact of adverse social factors on...
Emily C Liang,Megan J Shen,Rachel B Salit et al.
Emily C Liang et al.
Fear of cancer recurrence (FCR) is a significant challenge faced by hematopoietic cell transplantation (HCT) survivors, yet it remains insufficiently characterized in this group, limiting the ability to develop interventions to reduce FCR. ...
GVHD prophylaxis with ATG and PTCy versus PTCy-based regimens in haploidentical stem cell transplantation: A CTTC study [0.03%]
allo-HSCT半相合移植ATG/PTCy与改良PTCy方案预防GVHD的前瞻性研究
Alejandro Garcia-Horton,Brittany Salter,Kristjan Paulson et al.
Alejandro Garcia-Horton et al.
Background: Graft-versus-host disease (GVHD) remains a barrier to long-term success of haploidentical donor (HID) allogeneic hematopoietic cell transplantation (HCT). Post-transplant cyclophosphamide (PTCy) is considered ...
Survival advantage of reduced-toxicity conditioning in haploidentical hematopoietic cell transplantation for severe aplastic anemia patients with pre-transplant comorbidities [0.03%]
单倍型造血干细胞移植治疗移植前存在合并症的重型再生障碍性贫血患者的生存优势分析
Fan Lin,Zhengli Xu,Tingting Han et al.
Fan Lin et al.
Rates and Outcomes of Cardiovascular Complications in Critically Ill Blood or Marrow Transplant Patients: A Retrospective Cohort Study [0.03%]
重症血细胞或骨髓移植患者的心血管并发症发生率和结局：回顾性队列研究
Isabella C Blackman,Kevin J Psoter,Michael P Croglio et al.
Isabella C Blackman et al.
Background: Blood or marrow transplant (BMT) is an increasingly utilized treatment for hematologic disease, with approximately 20,000 procedures performed in the United States each year; up to a third of these patients wi...
Feasibility and safety of physical rehabilitation interventions in oncohematologic patients following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis [0.03%]
异基因造血干细胞移植患者康复干预的可行性和安全性系统评价和meta分析
R Pérez-Aguilar,J A Pérez-Simón,M Pabón-Carrasco et al.
R Pérez-Aguilar et al.
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) induces profound physiological disruption across immune, metabolic, and musculoskeletal systems. Despite advances in conditioning regimens and sup...
Comment on "Can Cord Blood Unit Selection Improve Outcomes After Single-Unit Unrelated Cord Blood Transplantation for Non-Remission Acute Myeloid Leukemia?" [0.03%]
论著《脐带血单元选择能否改善无关单份脐带血移植治疗非完全缓解急性髓系白血病患者的预后？》的评论
Yashkumar Kiranbhai Rajvi,Mohit Kumar,Dr Shubham Singh
Yashkumar Kiranbhai Rajvi
Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI [0.03%]
移植后环磷酰胺对HCT-CI预后价值的影响
Ansh Mehta,Haesook T Kim,Arcita Pramudita et al.
Ansh Mehta et al.
The hematopoietic cell transplant comorbidity index (HCT-CI) is a validated prognostic tool for baseline assessment in allogeneic hematopoietic cell transplantation (HCT). The impact of the individual components of the HCT-CI on prognosis r...